KEY POINTS
- NRG-BR002 was a multicenter randomized phase II/III trial conducted in the United States and Canada. Of 129 enrolled patients, 125 were eligible, with controlled primary breast cancer, four or fewer metastases, and no progression during up to 12 months of first-line systemic therapy.
- Patients were randomized 1:1 to continued systemic treatment alone or systemic therapy plus metastasis-directed ablation of all visible lesions using SBRT or surgical resection. 93% of ablation treatment was delivered with SBRT, making this the principal local intervention.
- Median age was 54 years; 79% of patients had hormone receptor-positive/HER2-negative disease, 60% had solitary metastases, 50% had bone involvement, and 37% had bone-only metastatic disease. The cohort therefore predominantly represented systemic therapy-responsive, limited-burden metastatic breast cancer.
- With 72 PFS events and median follow-up of 29.9 months, median PFS was 23.0 months without ablation versus 19.5 months with ablation. The difference was not significant (HR 0.92, 95% CI 0.57–1.47; one-sided p=0.36; stratified p=0.42).
- The phase II efficacy criterion was not met, and NRG-BR002 did not proceed to phase III. Overall survival was likewise not improved by ablation (HR 1.07, 95% CI 0.60–1.89; one-sided p=0.41; stratified p=0.52).
- No grade 5 toxicities occurred. Nevertheless, adding metastasis-directed therapy introduced an additional local treatment intervention without demonstrating improvement in either major survival endpoint.
- Exploratory circulating tumor cell analyses suggested that patients with low or absent pretreatment circulating tumor cells might experience improved PFS with ablation. This potential biomarker interaction remains hypothesis-generating and requires prospective validation.
CLINICAL TAKEAWAY
NRG-BR002 challenges the assumption that ablating every visible metastasis necessarily improves outcomes in oligometastatic breast cancer already controlled by first-line systemic treatment. Routine metastasis-directed SBRT or surgery did not improve PFS or OS in this selected population and should not be added solely to prolong survival outside clinical trials, although local therapy remains appropriate for palliation and specific clinical indications.